化疗引起的中性粒细胞减少症治疗市场- 按治疗类型（G-CSF、抗生素、粒细胞输注、抗真菌药）、药物类型（品牌、生物仿製药）、给药途径（肠胃外、口服）、配销通路与预测，2024 - 2032 年

由于批准生物相似药的有利监管途径以及处方者和患者的接受度不断提高，全球化疗引起的中性粒细胞减少症治疗市场规模在 2024 年至 2032 年期间复合年增长率将达到 3.7%。

包括癌症在内的慢性疾病的盛行率是市场的主要成长因素。根据CDC报告，在美国，每年有170万人被诊断出罹患癌症，导致超过60万人死亡，成为第二大死因。癌症治疗费用不断增加，预计到 2030 年将超过 2,400 亿美元。对 CIN 合理管理的需求不断增长，凸显了生物相似药等创新治疗方案的可行性。透过为传统治疗提供具有成本效益的替代方案，生物相似药满足了对可获取且具有成本效益的中性粒细胞减少症治疗日益增长的需求，从而推动了市场成长。

化疗引起的中性粒细胞减少症治疗行业根据治疗类型、药物类型、给药途径、配销通路和地区进行分类。

到 2032 年，生物相似药领域将快速成长，因为它们提供了传统疗法的经济高效的替代方案。用于治疗中性粒细胞减少症的生物相似药的可用性不断增加，使医疗保健提供者有机会优化治疗方案，同时降低医疗保健成本。此外，由于全球医疗保健基础设施面临越来越大的压力，需要在不影响患者护理的情况下控製成本，生物相似药的引入是一种有吸引力的解决方案，可以减轻财务负担，同时保持安全标准，这将推动该领域的成长。

由于便利性和灵活性，口服製剂细分市场将在 2024 年至 2032 年期间适度成长。治疗中性粒细胞减少症的口服溶液的开发使得以患者为中心的治疗成为可能，这样人们就可以在门诊甚至在舒适的家中接受治疗。此外，药物传递技术的创新提高了口服製剂的生物利用度和药物动力学，进一步增加了其使用。

由于强大的医疗基础设施和高癌症发病率，欧洲化疗引起的中性粒细胞减少症治疗行业规模将在 2024 年至 2032 年间强劲增长。在肿瘤学投资和先进治疗方法的采用的推动下，德国、英国和法国等国家正在引领产业成长。此外，製药公司和研究机构之间的合作使得中性粒细胞减少症新疗法的开发和商业化成为可能。该地区积极主动的癌症治疗方法和有利的政策有助于其在全球市场中的显着地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 癌症盛行率增加
    • 越来越多采用化疗
    • 治疗方案的技术进步
    • 政府措施和资金不断增加
  • 产业陷阱与挑战
    • 治疗费用高
    • 治疗的不良反应
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 粒细胞集落刺激因子治疗
• 抗生素
• 粒细胞输注
• 抗霉菌药
• 其他治疗类型

第 6 章：市场估计与预测：按药物类型，2021 - 2032 年

• 主要趋势
• 品牌化
• 生物相似药

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 注射用
• 口服

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Amgen Inc.
• BeyondSpring Inc.
• Biocon Biologics Inc.
• Cellerant Therapeutics
• Coherus BioSciences, Inc.
• Evive Biotech
• Kyowa Kirin Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Spectrum Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.

The global chemotherapy-induced neutropenia treatment market size will register 3.7% CAGR during 2024-2032, owing to favorable regulatory pathways for approval of biosimilars and growing acceptance among prescribers and patients.

Prevalence of chronic diseases including cancer is a major growth factor for the market. According to the CDC report, in the US, 1.7 million people are diagnosed with cancer annually, with over 600,000 fatalities, making it the second leading cause of death. The cost of cancer care is continually increasing and is projected to exceed $240 billion by 2030. As the cases of cancer surge worldwide, so does the use of chemotherapy as a treatment modality, increasing the likelihood of chemotherapy-induced neutropenia (CIN). This growing demand for rational management of CIN highlights the viability of innovative treatment options such as biosimilars. By providing cost-effective alternatives to conventional treatments, biosimilars address the growing need for accessible and cost-effective neutropenia treatments, which is driving market growth.

Chemotherapy-induced neutropenia treatment industry is classified based on treatment type, drug type, route of administration, distribution channel, and region.

The biosimilars segment will grow rapidly through 2032, as they offer cost-effective alternative to conventional therapies. The increasing availability of biosimilars for the treatment of neutropenia has given healthcare providers the opportunity to optimize treatment regimens while reducing healthcare costs. Additionally, as healthcare infrastructure worldwide is under increased pressure to contain costs without compromising patient care, the introduction of biosimilars is an attractive solution to lighten the financial burden while maintaining safety standards, which will drive growth in the segment.

The oral formulations segment will grow moderately during 2024-2032, due to the convenience and flexibility. The development of oral solutions to treat neutropenia enable patient-centered treatments so that people can receive treatment on an outpatient basis or even in the comfort of their own home. In addition, innovations in drug delivery techniques have increased the bioavailability and pharmacokinetics of oral formulations, further increasing their use.

Europe chemotherapy-induced neutropenia treatment industry size will grow strongly between 2024 and 2032, due to robust healthcare infrastructure and high incidence of cancer. Countries such as Germany, the United Kingdom and France are leading industry growth, fueled by investments in oncology and the adoption of advanced treatments. In addition, collaboration between pharmaceutical companies and research institutes enables the development & commercialization of new treatments for neutropenia. The region's proactive approach to cancer treatment and favorable policies contribute to its notable position in the global market.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Growing adoption of chemotherapy
    • 3.2.1.3 Technological advancements in treatment options
    • 3.2.1.4 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Adverse effects of treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Granulocyte colony-stimulating factor therapy
• 5.3 Antibiotics
• 5.4 Granulocyte transfusion
• 5.5 Antifungals
• 5.6 Other treatment types

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Biosimilars

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Parenteral
• 7.3 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Amgen Inc.
• 10.2 BeyondSpring Inc.
• 10.3 Biocon Biologics Inc.
• 10.4 Cellerant Therapeutics
• 10.5 Coherus BioSciences, Inc.
• 10.6 Evive Biotech
• 10.7 Kyowa Kirin Co., Ltd.
• 10.8 Novartis AG
• 10.9 Pfizer Inc.
• 10.10 Sanofi
• 10.11 Spectrum Pharmaceuticals
• 10.12 Teva Pharmaceutical Industries Ltd.